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RESUMO 
A malária é uma das doenças parasitárias mais antigas e continua a ser a que mais mortes 
provoca mundialmente atualmente. Pode ser causada por cinco espécies distintas de 
protozoários do género Plasmodium (P. falciparum, P. ovale, P. vivax, P.malariae e P. 
knowlesi), sendo o P. falciparum a espécie mais letal. O parasita é transmitido ao ser 
humano pela picada do mosquito fêmea do gênero Anopheles. aquando da refeição 
sanguínea. Em 2017, a Organização Mundial da Saúde relatou 219 milhões de casos de 
malaria em todo o mundo, sendo a grande maioria na região subsaariana do continente 
africano. A doença pode ser classificada como: malária grave e não grave, afetando 
principalmente crianças com idade inferior a cinco anos. As resistências aos fármacos 
antimaláricos em uso, bem como a inexistência de uma vacina eficaz e o difícil controlo 
vectorial são os principais obstáculos no combate à doença. A disseminação das 
resistências torna imperativo a investigação e síntese de novos compostos com potencial 
ação antimalárica, capazes de atuar em diversos estádios do desenvolvimento do parasita, 
rapidamente. 
 
Neste trabalho, procedeu-se à caracterização da atividade antimalárica e do modo de ação 
de compostos sintetizados. Compostos sintetizados para serem inhibidores de 
fosfodiesterases (PDEs) e de dihydroorotate dehydrogenase (DHODH) parasitárias 
(enzimas importantes para os diferentes estádios de desenvolvimento de P. falciparum). 
 
Para a análise da atividade antimalárica, foi avaliado a velocidade de ação dos compostos, 
os estádios parasitários em que os compostos têm maior atividade, bem como a sua 
toxicidade nesses estádios. Foram também otimizados dois protocolos de modo a poder, 
posteriormente, avaliar a ação dos compostos na produção de espécies reativas de 
oxigénio (ROS) e na alteração do potencial da membrana mitocondrial do parasita.  
 
Avaliando a atividades antimaláricas dos potenciais inibidores de PFPDE, um dos 
compostos demostrou ser de atuação rápida, com atividade nos dois estádios eritrocitários 
e ter um efeito citocida nos parasitas. O segundo composto com potencial ação contra os 
PFPDEs avaliado, demostrou ser de atuação mais lenta, com uma ação predominante nos 
parasitas no estádio de anel, mas tendo um efeito citocida. O composto com potencial 
ação contra os PFDHODH demostrou ser de atuação lenta, com uma ação predominante 
com um efeito citocida nos parasitas no estádio de anel e um efeito citostático nos 
parasitas no estádio de trofozoítos. 
 
Palavras-chave: malária, Plasmodium falciparum, antimaláricos, modo de ação, PDEs, DHODH, 
ROS, potencial da membrana mitocondrial. 
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Abstract 
Malaria is one of the oldest parasitic diseases and continues to be the one that causes the 
most deaths worldwide nowadays. It can be caused by five distinct species of Plasmodium 
(P. falciparum, P. ovale, P. vivax, P.malariae and P. knowlesi), with P. falciparum being 
the most lethal. The parasite is transmitted to humans by the bite of the female mosquito 
of the genus Anopheles during the blood meal. In 2017, WHO reported 219 million 
malaria cases worldwide, with the vast majority in the sub-Saharan region. The disease 
can be classified as: severe and non-severe malaria, mainly affecting children under five 
years old. Resistance to antimalarial drugs in use as well as the lack of a effective vaccine 
and the difficult vectorial control are the main obstacles in the fight against the disease. 
The dissemination of resistance makes it imperative to investigate and synthesize new 
compounds with potential antimalarial action, capable of acting at several stages of 
parasite development, rapidly. 
 
In this work, the antimalarial activity and the mode-of-action of synthesized compounds 
were studied. Compounds synthetized to be phosphodiesterase’s (PDEs) and 
dihydroorotate dehydrogenase (DHODH) inhibitors (important enzymes for Plasmodium 
falciparum different stages of development). 
 
For the analysis of the antimalarial activity, the speed of action of the compounds was 
evaluated, the stage-specific activity and toxicity of the compounds were determinate. 
Two protocols were also optimized, in order to evaluate, later, the action of the 
compounds, in the production of reactive oxygen species (ROS) and in the alteration of 
mitochondrial membrane potential. 
 
Evaluating the antimalarial activities of the potential inhibitors of PFPDE, one of the 
compounds was shown to be fast acting with activity in both erythrocyte stages studied 
and to have a cytocidal effect on the parasites. The second compound with potential action 
against the PFPDEs evaluated, showed to be of slower action, with a predominant action 
in the ring-stage parasites, but having a cytocidal effect. The compound with potential 
action against PFDHODH shown to be a slow acting compound, with a predominant 
action in the ring-stage parasite and to have a cytocidal effect on the ring-stage parasites 
and a cytostatic effect on trophozoite-stage parasites. 
Key words: malaria, Plasmodium falciparum, antimalarials, mode of action, PDEs, 
DHODH, ROS, mitochondrial membrane potential. 
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I.1. MALARIA  
Malaria is one of the oldest diseases known to affect human kind. The characteristic 
periodic fever of the disease is described in antique Chinese literature dating back to 2700 
BC. Hippocrates (5th century BC) was the first to describe the disease. However, only in 
the 19th century, the causative agent of the disease was identified. In 1897, Ronald Ross 
discovered Plasmodium falciparum oocysts in an anopheline mosquito fed on patients 
suffering from malaria, and later was able to observe all the stages of the parasite as also 
described by Laveran in mosquitos fed on infected malaria birds (Knell, 1991). 
 
Malaria is distinguished in two categories by the World Health Organization (WHO), 
uncomplicated malaria and severe malaria. The first symptoms of the disease are identical 
to a common viral illness and can appear up to fifteen days after the contact with the 
vector. It provokes headache, fatigue, abdominal discomfort, muscle and joint aches, 
fever usually followed by chills and perspiration, anorexia, and vomiting. In young 
children, it usually also causes lethargy, loss of appetite and cough (White et al., 2014). 
It is considered uncomplicated malaria when patients present the symptoms presented 
above and a positive parasitological test diagnostic (microscopy or rapid diagnostic test). 
If not treated correctly in the first twenty-four hours, it can develop into severe malaria 
and to death. It is considered severe malaria when the patient present one of the following 
symptoms, with no other identified alternative cause and in the presence of P. falciparum 
asexual parasitaemia according to WHO. The symptoms observed in severe malaria can 
be cerebral coma, severe anaemia, hypoglycaemia, metabolic acidosis, acute renal failure 
and acute pulmonary oedema. Severe malaria is fatal in most of the cases (WHO, 2015). 
The treatment is focused on eliminating all the parasites from the body of the patient, 
preventing the passage to severe malaria, avoiding malaria relapse and recrudescence, 
interrupt the transmission of the parasite and to prevent the emergence and spread of 
resistance to antimalarial drugs. WHO recommends different treatments according to if it 
is considered uncomplicated malaria, severe malaria or if it is patients with uncomplicated 
malaria in special risk groups (pregnant women, infant with less than 5 Kg body weight, 
patients co-infected with HIV, non-immune travellers, patients with uncomplicated 
hyperparasitaemia) (WHO, 2015).  
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I.2. MALARIA: GEOGRAPHICAL DISTRIBUTION AND GLOBAL 
EPIDEMIOLOGY 
 
Malaria remains one of the deadliest vectors born-diseases in low-income countries. 
Nearly half of the world’s population was at risk of contracting malaria in 2017 according 
to the WHO. Malaria is considered endemic in the tropical and subtropical regions (Figure 
I.1) and affect mainly sub-Saharan where 93% deaths due malaria occurs. In other parts 
of the world it causes considerable morbidity, particularly in rural areas of the countries 
of the South-East Asia region and the eastern Mediterranean region. The WHO has 
estimated that the incidence rate of malaria and malaria deaths rate has decreased by 37% 
and 60% globally between 2000 and 2015 but despite these reductions, a substantial 
increase in malaria cases has been estimated since 2015. WHO reported an increase of 
five million clinical cases in 2016 compared to 2015 and a total of 445 000 deaths 
worldwide(WHO, 2015b). 
 
 
Figure I.1. Distribution of indigenous cases of Malaria in 2016. Adapted from 
(WHO, 2017). 
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Plasmodium spp. are transmitted to humans by female Anopheles mosquitos’ bites during 
the blood meal that can take place indoors or outdoors. The disease can be caused by five 
different species of the genus Plasmodium: P. falciparum, P. vivax, P. ovale, P. malariae 
and P. knowlesi, with P. falciparum being the deadliest to humans. Every person can be 
infected by the protozoan, but some groups in the population such as children under five 
years old, pregnant women and immunocompromised peoples are more likely to be 
infected and to be more seriously ill (Ashley et al., 2006). 
 
I.3. LIFE CYCLE OF THE PARASITE 
 
The parasite has a complex life cycle (Figure I.2), in which it needs two hosts to be able 
to complete; some hematophagous female of the Anopheles mosquitos are the definitive 
hosts in which occurs the exogenous sexual phase, called sporogony phase and some 
vertebrates are the intermediate hosts in which occurs the endogenous asexual phase 
called schizogony phase (Antinori et al., 2012). The sporogony phase take place after a 
blood meal in an infected vertebrate in which the mosquitos ingest gametocytes (sexual 
stage - male and female) that fuse in the midgut to form zygotes that develops into oocysts. 
After maturation, the oocysts grow into sporozoites and migrates to the salivary glands of 
the mosquitos where it can be transferred to a new vertebrate host during the blood meal. 
In the vertebrates, sporozoites migrates to the liver where they develop into schizonts and 
the schizonts divide by asexual reproduction generating merozoites. This phase is called 
preerythrocytic phase. It can last about one to two weeks and can be asymptomatic. After 
rupture of the hepatocytes, the merozoites enter the bloodstream and infects erythrocytes. 
In the red blood cells, some merozoites develops, into gametocytes and some develops 
into young trophozoites called “rings”, which mature in trophozoites and then into 
schizonts, consuming haemoglobin. Gametocytes, the stage that transmit the infection, 
has four stages of developments in which in the fourth occurs the differentiation into male 
and female, are “banana” shaped and can take seven to ten days to develops in P. 
falciparum. Schizonts after maturing, rupture the cells releasing more merozoites into the 
bloodstream thus restarting the cycle. The rupture of the blood cells provokes the 
symptoms characteristic of malaria, the fever. This phase is called erythrocyte phase and 
can last until lysis of the erythrocytes if left untreated. In the infection by P. falciparum 
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all the schizonts mature into merozoites. In the infection by P. vivax and P. ovale, the 
merozoites may develop latent hepatic forms, the hypnozoites, and begin a new 
erythrocyte cycle months or years later (Cowman et al., 2016). 
 
 
Figure I.2. Life cycle of Plasmodium spp. Adapted from (Cowman et al., 2016). 
 
 
I.4. MALARIA CONTROL 
 
Presently WHO’s strategy to control and eliminate malaria, is based on: vector control; 
the development of an effective vaccine; chemotherapy; and chemoprophylaxis. The 
vector control mainly aims to reduce the vectorial capacity of the vector below the critical 
threshold necessary for the transmission of the parasite. This purpose is achieved by 
decreasing the number of vectors on the transmission phase and by limiting the contact 
frequency between the vector and the human population. The main vector control 
methods used nowadays are based on ecological, biological, chemical and genetic control. 
Briefly, the ecological control can be directed to the larval or/and the adult form of the 
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mosquitos by improving health infrastructures and managing aquatic habitats potentially 
favourable to mosquito breeding. Biological control is based on the use of synthesized 
biological products that can change the development and/or behaviour of the vector or by 
introducing natural enemies in the ecosystem. Chemical control is achieved by applying 
outdoor and/or indoor residual spraying (IRS), insect repellents and using insecticide-
treated bed-nets (ITNs). Genetic control of the vector, in turn, is based on the principle of 
causing or introducing in the vector genetic alterations that are disadvantageous to the 
vector or to the pathogen it carries, and which can lead to its elimination (Tizifa et al., 
2018). 
 
Due to the complexity of malaria parasites biology, the development of an effective 
vaccine against the disease hasn’t been successful so far. There is no available malaria 
vaccine in the commerce currently, but more than 20 vaccine constructs are currently 
being evaluated in clinical trials or are undergoing preclinical development and recent 
progress has been made with the completion of a Phase 3 trial of the RTS, S/AS01 
candidate vaccine (WHO, 2017). 
 
Since 2010, for the chemotherapy in the case of uncomplicated malaria, WHO 
recommends artemisinin-based combination therapy (ACTs) when the disease is caused 
by the P. falciparum parasite. When the disease is caused by P. vivax, P. ovale, P. 
malariae or P. knowlesi the treatment is based on chloroquine-based treatment, 
primaquine or ACTs when it is a zone with chloroquine-resistant parasites. The treatment 
is recommended to be done during three successive days to ensure the adequate efficacy 
and minimize the risk of the drug resistance due to incomplete treatment. When the 
disease in considered severe malaria, WHO recommend treating patients with intravenous 
or intramuscular artesunate for minimum 24h until they can tolerate oral medication and 
once it is possible, a three consecutive days ACTs treatment. For patients in special risk 
groups, WHO preconise different approaches as appropriate. For women in the first 
trimester of pregnancy, for example, a seven-day treatment with clindamycin in addition 
to quinine, is recommended to avoid adverse effects on the mother or the foetus that may 
be cause by others antimalarials. 
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Chemoprophylaxis is based on the use of complete treatment as prophylaxis and is 
recommended when traveling to affected areas, during the potential exposition to malaria 
and up to four weeks after the exposure (Walker, Nadjm and Whitty, 2018). WHO 
presently recommended three preventive therapies against the disease: Intermittent 
preventive malaria treatment in pregnancy (IPTp) and in infant (IPTi) with sulfadoxine-
pyrimethamine; and seasonal malaria chemoprevention for children aged 3-59 month to 
avoid the disease (WHO, 2017). 
 
Malaria is a preventable and curable disease if diagnosed in time. The main diagnosis test 
used is the thick and thin blood film Giemsa stained microscopy test. Useful for detecting 
blood-stage parasite, the thick blood film test, a sensitive test, indicates the presence or 
the absence of parasites in the blood, meanwhile the thin blood film test, a more specific 
test, indicate the specie and abundance of the parasite in the blood. 
Immunochromatographic rapid diagnostic tests (RDTs), also a sensitive test, detect 
antigens or parasite-specific enzymes. It is also widely used to detect the presence or 
absence of the parasite in the bloodstream, principally in remote areas with limited access 
to good microscopy services, (WHO, 2017) or as an additional test in non-endemic areas 
where few cases are observed annually (Walker, Nadjm and Whitty, 2018). The 
Polymerase chain reaction (PCR), a very sensitive test, is used to detect low-intensity 
malaria infections, but due to its elevated cost, low availability and the amount of time 
needed to obtain the results, the WHO only recommended using it for epidemiological 
research and sub-microscopic infection mapping. 
 
I.5. THE PARASITE 
 
The protozoan parasites belonging to the Plasmodium genus, is the causative agent of the 
disease. It’s a unicellular Eukaryota, belonging to the Apicomplexa phylum, to the 
Aconoidasida class, to the Haemosporida order and to the Plasmodiidae family (Antinori 
et al., 2012). Plasmodium spp (like other apicomplexans parasites) has several structures. 
The rhoptries containing parasite proteins that help in the invasion and modification of 
the host once the parasite is inside. The micronemes that contains parasite proteins 
indispensable for mobility, identification and attachment to host cells. Spread all over the 
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parasite, dense granules containing parasite proteins involved in the modification of the 
membrane that separates the parasite from the host (Morrissette and Sibley, 2002). The 
parasite is also composed by a single large mitochondrion and the apicoplast, two 
organelles of endosymbiotic origin, who are indispensable for the parasite’s metabolism. 
The mitochondrion is responsible for the production and transport of energy in form of 
Adenosine triphosphate (ATP) by means of the electron transport chain. The apicoplast, 
in turn, is involved in the synthesis of different metabolic mechanism such as protein, 
DNA and isoprenoid synthesis. The digestive vacuole (DV) is involved on the haem 
polymerization, the haemoglobin hydrolysis and free-radicals generation (Fidock et al., 
2004).  
 
I.6. ANTIMALARIAL DRUGS 
 
I.6.1. CURRENT ANTIMALARIAL DRUGS 
 
Antimalarial drugs primarily aim at eliminating blood stage parasites as quickly as 
possible, so as to prevent the disease to progress to more severe forms and even death. In 
terms of public health, it is intended to reduce the transmission of infection among the 
population and to prevent the emergence and dispersion of resistance to antimalarials 
(WHO, 2016). 
 
Since 2010, WHO recommends only administering antimalarials following confirmatory 
diagnosis by microscopy or rapid diagnostic tests (WHO, 2015a). Since 2001, WHO has 
recommended that artemisinin-based combination therapy (ACT), by 2010 most malaria 
endemic countries had shifted their national treatments policies to ACTs (WHO, 2010). 
ACTs consist of combining an artemisinin derivative (ARTs) with a partner drug, with a 
longer half-life, different pharmacophore and mechanism of action (WHO, 2015). In 
ACTs, the artemisinin derivative (being a fast-acting drug) plays a role in drastically 
reducing the number of parasites in the first 3 days of treatment. While the partner drug 
(slower acting) eliminates the residual parasites (WHO, 2015). Some of the other 
advantages that lead to the use of ACT are: to rapidly reduce parasitaemia, rapid 
resolution of clinical symptoms, action against multidrug resistant P. falciparum and have 
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activity against gametocytes, allowing a decrease in transmission (WHO, 2015). Drug 
regimens for treatment of the two most prevalent malaria 
parasites, P. falciparum and P. vivax, are different. Chloroquine (CQ) plus primaquine 
(PQ) remain the first-line treatment for radical cure of P. vivax malaria in most malarious 
regions (Walker, Nadjm and Whitty, 2018). Available antimalarial drugs can be divided 
into multiple classes (Table I.1). 
 
The first important antimalarial drug discovered in history was the alkaloid quinine, from 
the “Peruvian fever tree” Peruvian bark Cinchona named by Linnaeus in 1749 (Knell, 
1991). It was brought to Europe from South America in the 17th century, because of its 
known medical values for curing and treating fevers. Quinine and its derivatives are 
known to target blood stages of the parasite, particularly trophozoites and early stage 
gametocytes, causing clumping of hemozoin and producing nuclear and cytoplasmic 
degeneration (Knell, 1991;Haldar, Bhattacharjee and Safeukui, 2018). Quinine (QN) is 
an arylamino alcohol that is the oldest antimalarial drug used as cinchona bark since the 
1600s and its pure since 1820 (Rosenthal, 2001). It produces severe side effects, and its 
use is practically limited to the treatment of severe malaria. 
 
Important malaria-related drugs are mefloquine (MEF) and lumefantrine (LUM), 
components of the ACTs artesunate/mefloquine (AS/ MEF) and artemether/lumefantrine 
(ATM/ LUM).  
 
During the Word War II, an alternative to QN was developed since it was no longer 
available to the US troops. They were able to produce CQ, belonging to a new class of 
antimalarials; the 4-aminoquinolines. CQ targets the polymerization of free haem into a 
crystal called hemozoin, within the food vacuole of trophozoites and schizonts. The 4-
aminoquinoline, CQ, was the mainstay for the treatment of uncomplicated malaria for 
decades. Due to its low price and negligible side effects, CQ became (together with the 
insecticide DDT), the mainstay of malaria control worldwide. A decade after its massive 
use, the first signs of resistance emerged and by the 1980s CQ-resistant parasites were 
widely spread in the malarious regions (Butler, Khan and Ferguson, 2010; Haldar, 
Bhattacharjee and Safeukui, 2018). Currently drug resistance to CQ has spread to nearly 
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al malarious regions, render it inappropriate for the treatment of P. falciparum malaria. 
In Indonesia, the emergence of P vivax resistance to CQ prompted a policy change to 
ACTs also (Baird, 2011). 
 
Amodiaquine (AMQ) probably has the same resistance mechanisms as CQ, but because 
it has higher potency it is still effective against many CQ-resistant parasites, and it is a 
component of the recommended ACTs (Folarin et al., 2011). 
 
The more recently introduced piperaquine (PPQ), was widely used to treat malaria in 
China for decades, now is declining because of increasing drug resistance (Davis et al., 
2005; Ashley and Phyo, 2018). It is currently, a component of the ACT, 
dihydroartemisinin/ piperaquine (DHA/ PPQ) (WHO, 2015) 
 
The 8-aminoquinoline primaquine (PQ), even thought, it has some activity against blood 
stage parasites, it is mostly used to eliminate parasite liver stages (and dormant forms - 
hypnozoites of P. vivax and P. ovale) (Ashley and Phyo, 2018). PQ is also active against 
gametocytes, reducing transmission of parasites to mosquito vectors (Ashley and Phyo, 
2018). The WHO recommends the use of a single dose of PQ in combination with ACTs 
for P. falciparum malaria treatment in order to decrease transmission (WHO, 2015a). 
Antifolates drugs target parasite dihydrofolate reductase (DHFR) and dihydropteroate 
synthase (DHPS) (Ashley et al., 2006). Sulfadoxine/pyrimethamine (SP) has the 
advantage of being single-dose therapy, but its efficacy is currently seriously limited by 
disseminated drug resistance (Barnes et al., 2008). SP, antifolate drugs, began to be used 
in 1948 and 1967 respectively, targeting liver stage parasites and blood stage parasites, 
but rapidly presented resistance. SP inhibit the P. falciparum enzymes dihydropteroate 
synthase (Pfdhps) and dihydrofolate reductase (Pfdhfr), which function in the folate 
pathway (Haldar, Bhattacharjee and Safeukui, 2018). 
 
The naphthoquinone atovaquone (ATQ), introduced in later in 1996, acts against the 
mitochondrial cytochrome bc1 complex (Van Voorhis et al., 2016). Combined with the 
DHFR inhibitor proguanil the, commercially available Malarone (although expensive 
therapy), is largely recommended for as chemoprophylaxis to travelers (Ashley et al., 
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2006). ATQ combined to proguanil dissipate mitochondrial membrane potential leading 
to the release of cytochrome C and to the apoptosis of the parasite (Haldar, Bhattacharjee 
and Safeukui, 2018). It is noteworthy that the synergy of this combination appears to be 
independent of inhibition of folate synthesis (Cui et al., 2015). 
 
Antibiotics such as doxycycline, clindamycin and tetracycline, are also used as 
antimalarials, because of their action against the protein synthesis machinery of the 
apicoplast (Dahl and Rosenthal, 2008). 
 
Currently, artemisinin derivatives (ARTs) are the most significant group of antimalarials 
it was developed from a natural product, extracted from the plant Artemisia annua, the 
active compound was isolated in 1971 in China (Cui and Su, 2009). Artemisinin (ART) 
is a potent antimalarial. Artemisinin-based combination therapy (ACTs) are currently the 
most effective and the mainstay of recommended treatment since 2006 by WHO to treat 
uncomplicated P. falciparum malaria. The ARTs artesunate (AS), artemether (ATM) and 
dihydroartemisinin (DHA) are used as components of the ACTs (WHO, 2015a). ARTs 
are highly effective against malaria, but have a very short half live, so the combination 
with a longer-acting partner drug allows short treatments (3-day) that also protects against 
the selection of resistant parasites (Nosten and White, 2007). AS is also used for the 
treatment of severe P. falciparum malaria, with documented survival advantages 
compared with QN (Dondorp et al., 2005, 2010; WHO, 2015a). 
 
Five combinations of ACTs are preconized by WHO to use against malaria. Artemether 
+ Lumefantrine; Artesunate + Amodiaquine; Artesunate + Mefloquine; 
Dihydroartemisinin + Piperaquine, and Artesunate + Sulfadoxine-Pyrimethamine (SP) 
(WHO, 2017). 
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Table I.2. Currently used antimalarial drugs and respective targeted parasite stage 
(adapted from Haldar, Bhattacharjee and Safeukui, 2018) 
Chemical Class Common Name Target 
 
Sesquiterpene lactone 
Endoperoxides 
Artemisinin  
All parasite stages Artesunate 
Artemether 
Dihydroartemisinin 
 
 
 
4-Aminoquinolines 
Chloroquine Blood stages  
(trophozoites and 
schizonts) 
Amodiaquine 
Piperaquine 
 
Amino alcohols 
Quinine Blood stages  
(trophozoites and stage I to 
III gametocytes) 
Mefloquine Blood stages 
(trophozoites and 
schizonts) 
Lumefantrine 
Halofantrine 
8-Aminoquinoline Primaquine Blood (gametocyte) and 
liver (schizont) forms  
 
Antifolates 
Pyrimethamine Blood and liver schizont 
and mosquito stage 
(oocyst)  
Sulfadoxine Blood and liver schizont  
Proguanil Blood stages (schizont and 
gametocyte) and liver 
schizont 
Naphthoquinone Atovaquone Blood stages (schizont and 
gametocyte) and liver 
schizont  
Antibiotics Clindamycin  
Blood stages Doxycycline 
Tetracycline 
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I.6.2. ANTIMALARIALS DRUG RESISTANCE 
 
Drug resistance in malaria is almost exclusively related to P. falciparum, and will be the 
focus of our work, from hereon. 
The emergence of CQ resistant malaria was first identified in Southeast Asia and South 
America around 1960. Subsequently, CQ-resistant parasites spread of Africa increasing 
up to 3-fold malaria-related deaths, in the 1980s (Petersen, Eastman and Lanzer, 2011). 
An alternative to CQ was introduced SP however, about a year after implementation SP 
drug-resistance was identified (Wernsdorfer and Payne, 1991). Parasite resistance to SP 
spread quickly throughout Southeast Asia, and later to Africa (1990s decade) (Hurwitz, 
Johnson and Campbell, 1981; Verdrager, 1986), since then has rapidly spread throughout 
Africa as well (Arrow et al., 2004). 
Several other antimalarial drugs have since, been introduced as treatment regimens 
against malaria, including mefloquine, amodiaquine and quinine (Petersen, Eastman and 
Lanzer, 2011). The usage of these replacement drugs in monotherapies equally resulted 
in the selection of resistant parasites, in vast malarious regions  
 
 
Figure I.3. Geographic distribution of antimalarial drug resistant of Plasmodium 
falciparum, adapted from (Krungkrai and Krungkrai, 2016). Resistance to chloroquine 
and sulphadoxine-pyrimethamine are represented in blue and yellow circles, respectively. 
Resistance to artemisinin across the Great Mekong region in 2014, is shown in black dash area. 
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Mefloquine was introduced as a treatment drug around 1975 (Trenholme et al., 1975), 
and clinical evidence of parasites resistant to mefloquine began to appear in Southeast 
Asia around the time of its general availability in 1985 (Hoffman et al., 1985). 
 
The currently used treatment for malaria the ACTs, combine ART derivative with a 
partner drug of a distinct chemical class (Table I.1) (WHO, 2015). ACTs compensate for 
the poor pharmacokinetic properties of the ARTs and increase treatment efficacy, while 
reducing the emergence of drug-resistant parasites (Petersen, Eastman and Lanzer, 2011). 
Unfortunately, in 2008 reports observed the emergence of ART resistant parasites in 
Southeast Asia (Petersen, Eastman and Lanzer, 2011). Presently, ART drug resistance is 
disseminated across the Great Mekong region (Figure I.3) (Blasco, Leroy and Fidock, 
2017). The concomitant resistance to ACT partner drugs, resulted in high failure rates to 
certain ACTs, such as dihydroartemisinin + piperaquine (Leang et al., 2013, 2015; Lon 
et al., 2014; Duru et al., 2015; Spring et al., 2015; Amaratunga et al., 2016) or artésunate 
+ méfloquine (Carrara et al., 2013). In view of this and before P. falciparum malaria 
becomes untreatable, new antimalarial treatments are urgently needed. 
 
 
I.6.3 NEW ANTIMALARIALS KILLING PROFILE 
 
The different life cycle stages of P. falciparum provide several different targets for 
antimalarials, but to date, all drugs in clinical use act mainly against the intraerythrocytic 
development stages (figure I.4.). 
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Figure I.4. Plasmodium falciparum intraerythrocytic life cycle: stages of 
development, adapted from (Nogueira and Rosário, 2010). In vitro sorbitol synchronized 
culture parasites stained with DAPI (4’,6’-diamidini-2-phenylindole) and photographed under UV 
light in a fluorescence microscope (1,000 x). 
 
The most widely used drugs, act on the food vacuole and hemozoin formation of rings 
and trophozoites blood-stages (Zarchin, Krugliak and Ginsburg, 1986; Loria et al., 1999; 
Famin and Ginsburg, 2002; KRISHNA, UHLEMANN and HAYNES, 2004) or on 
enzymes in the trophozoite folic acid biosynthesis pathway (Ferone, Burchall and 
Hitchings, 1969; Yuthavong et al., 2006; Raphemot et al., 2016). Drugs that have been 
used clinically, have one of these two modes of action and include CQ, AMQ, QN, SP, 
ARTs (mostly artemether and artesunate) and LUM. Unfortunately, drug resistance has 
rendered many of these compounds ineffective, and there are reports of ARTs resistant 
parasites, across the Southeast Asia (Dondorp et al., 2009, 2017; Noedl, Socheat and 
Satimai, 2009) In fact, the delayed parasite clearance in response to ACTs has been 
observed clinically and is recognised as the phenotype for ART-resistant parasites (White 
et al., 2015; Dondorp et al., 2017). 
ARTs are fast acting drugs with marked parasiticidal effect, quickly relieving malarial 
symptoms and minimizing the chance for resistant parasite selection (Burrows et al., 
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2013). Replacement of ACTs requires the identification of new drugs with rapid parasite 
killing kinetics including stage specificity activity. 
In vitro parasite growth inhibition assays expose parasites to a compound during a period 
of time and at the end of incubation viability is assessed by labelling nucleic acids or 
measuring enzymatic activity (Machado et al., 2016). However, these approaches do not 
directly measure the speed of parasite killing, and the reliability of such tests depends on 
the drug mechanism of action (Wein et al., 2010; Sanz et al., 2012). A number of different 
approaches have been proposed for the in vitro identification of rapidly parasiticidal anti-
malarial drugs have been proposed (reviewed in Sinha et al., 2017). 
The development of resistance to antimalarials drugs over the years, the lack of new 
antimalarials drugs, the need of a fast acting, single dose drug with minimal toxicity and 
at a low price led to the active research for new drug with new mechanisms of action for 
the elimination of malaria. Following this purpose, over 6 million compounds against 
asexual-stage P. falciparum have been screened since 2007. This initiative was achieved 
by pharmaceutical companies (GlaxoSmithKline and Novartis) and by academic centres 
(St. Jude, Memphis and Eskitis, Australia). The screening has led to the creation of a 
library of compounds called the “Malaria Box”, which is freely distributed to researchers 
for further studies about different mechanism of action and antimalarial profile (Van 
Voorhis et al., 2016). 
For this thesis, compounds of the “Malaria Box” provided by Medicines for Malaria 
Venture (MMV), a Swiss non-profit organization that is committed in the development 
of new antimalarial drugs were used. The 2,3-dihydro-1H-pyrrolo[3.4-b]quinoline-
9(4H)-one (named Pyrroloquinolones), known to have a dual-stage activity against 
malaria parasite is a promising phosphodiesterase 5 (PDE5) (Zheng et al., 2018) and 
Plasmodium falciparum Dihydroorotate Dehydrogenase (PfDHODH) inhibitor. Since 
there are only few investigations about their antimalarial profile and mode of action, our 
laboratory in association with PhD Professor Rui Moreira’s group decided to study them. 
The PDEs represent an important family of enzymes that is essential for the degradation 
of the cyclic nucleotide in the second messenger signal through hydrolysis of cyclic 
adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) and 
-INTRODUCTION  
 17 
blocking their cellular signals. Presently, PDEs is constituted by 11 gene-related families 
of isozymes (PDE1 to PDE 11) (Keravis and Lugnier, 2012). High cytoplasmic levels of 
secondary messengers (cAMP, cGMP) allow the activation of proteins essential for the 
survival of P. falciparum (kinase A and G proteins responsible for the translation of 
monophosphate cell signals), specifically in gametogenesis and cell invasion (Beraldo et 
al., 2005). Phosphodiesterase control the production of these messengers, reducing their 
cellular accumulation (Ramdani et al., 2015). The P. falciparum genome encodes four 
highly similar PfPDEs, of which only two, PfPDEα and PfPDEβ, is related to be 
expressed in asexual blood stages (Baker et al., 2017a). By using phosphodiesterase 
inhibitors, the exponential increase of these cyclic nucleotides leads to successive events 
that inhibits the occurrence of a normal developmental cycle by Plasmodium falciparum, 
principally in the stages of erythrocyte invasion and gametogenesis 
Dihydroorotate dehydrogenase (DHODH) was already known to be a promising target 
for the development of new antimalarial drugs but has been confirmed using evolution-
based methods. DHODH is an enzyme localized in the mitochondrial electron transport 
chain (mETC), which provides oxidized ubiquinone as an electron acceptor for DHODH 
to synthesize the de novo pyrimidine (Luth et al., 2018). Pyrimidines are essential 
metabolites that are precursors of DNA and RNA biosynthesis. Cells acquire pyrimidines 
by de novo synthesis from ammonia (derived from L-glu), bicarbonate and L-asp, or by 
recovering preformed bases of pyrimidine (uracil, cytosine and thymine) or nucleosides 
(uridine, thymidine and cytidine). The parasite cannot save pyrimidines from its host, so 
the mETC activity is essential for cell growth (Phillips and Rathod, 2010). The use of 
PfDHODH as a drug target will lead to the collapse of the cell and to the death of the 
parasite. 
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Despite all the advances in research in the fight against malaria, the disease remains one 
of the deadliest in the world. Characterization of potential antimalarials mode of action, 
and the search for new and different parasite targets is a powerful tool to be prepared for 
potential ACT spread of resistance, since there are no other new known antimalarial 
available. 
 
In this context, this thesis aimed to test three compounds, synthetized by PhD Professor 
Rui Moreira’s group, belonging to the pyrroloquinolones family, known to be potential 
phosphodiesterase (PDEs) and dihydroorotate dehydrogenase (DHODH) inhibitors 
against P. falciparum. 
 
General objectives 
In vitro characterization of the antimalarial activity and mode of action of new PDEs and 
DHODH inhibitors against P. falciparum. 
 
Specific objectives  
1 - Evaluate the speed-of-action of the compounds. 
2 – Determine the stage-specific activity of the compounds. 
3 – Optimization of the protocols of reactive oxygen species and mitochondrial membrane 
potential. 
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III.1. REAGENTS 
III.1.1. COMPLETE MEDIUM SOLUTION FOR PLASMODIUM 
CULTURE 
 
To prepare one litre of complete medium solution (RPMIc), 10,44g of RPMI 1640 
(Gibco), 5,95g of HEPES (sigma) (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 
5g of AlbuMAX II (Invitrogen) and 0,1g of Hypoxanthine (Sigma) were dissolved in 
Milli-q water. After homogenizing the solvents for 30 minutes, 2g of sodium bicarbonate 
(Sigma) was added to have a neutral pH of 7,4 like in the human blood. For the storage, 
the medium was filtered, with a 0.22 µm pore into a sterile container and maintained at 
4ºC until its use. 
 
III.1.2. GIEMSA DYE SOLUTION 
 
The Giemsa dye solution at 20% was prepared adding 20 mL of Giemsa (VWR) 
concentrate in 80 mL of buffered water (Sigma). The solution was then filtered using filter 
paper and stored at 4ºC. 
 
III.1.3. D-SORBITOL SOLUTION 
 
D-Sorbitol solution at 5% was obtained by adding 50g of D-Sorbitol (VWR) to one litre 
of distilled water. The solution was filtered using a filter with a 0,22 µm pore into a sterile 
container and kept at 4ºC. 
 
III.1.4. PHOSPHATE BUFFERED SALINE SOLUTION (PBS) 
 
For a 400 mL PBS solution, 2 PBS effervescent tablets (VWR) were dissolved in 400 mL 
Milli-q water. The solution was then autoclaved to ensure its sterility and maintained at 
4ºC.  
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III.1.5. CYTOMETER CLEANING REAGENT  
 
To clean the cytometer, a sodium azide solution were prepared. For 100 ml of Milli-Q 
water, 10g of sodium azide in powder were added. 
 
III.1.6. COMPOUNDS, DYES AND DRUGS 
 
• MS 092 
• MS 105 
• GS 082 
• CQ, Chloroquine 
• ATQ, Atovaquone 
• CM-H2DCFDA (InvitrogenTM) 
• SYTOTM61 (InvitrogenTM) 
• Rhodamine 123 (Sigma-Aldrich)  
 
The compounds to be tested were synthetized and provided by the colleagues of the 
“Faculdade de Farmácia da Universidade de Lisboa” advised by the PhD Professor Rui 
Moreira. 
MS 092 and MS 105 were synthetized from selective inhibitors targeting PfDHODH and 
GS 082 from inhibitors targeting PDEs, presenting a mechanism of action involving 
interactions with cell signalling pathway and mitochondrial function.(Harris et al., 2013) 
All of them chosen according to their activity against the erythrocyte and hepatic stage of 
the parasite.  
Each compound was dissolved in DMSO. For the MS 092, MS105 and GS 082, the 
dissolution was made to acquire a solution with a final concentration of 5mM. For the 
chloroquine and atovaquone, the final concentration was 10µM. the solutions were stored 
at -20ºC until use. 
Chloroquine and/or atovaquone were used as the positive controls for all the assays since 
they are standards drugs used against P. falciparum parasites. Chloroquine binds to 
ferriprotoporphyrin IX, a product of haemoglobin degradation inhibiting hemozoin 
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polymerization. Atovaquone interferes with parasite mitochondrial electron transport and 
depolarizes the parasite mitochondria membrane thereby blocking cellular respiration 
(Farrar et al., 2014). 
III.2. BIOLOGICAL MATERIALS 
III.2.1. RED BLOOD CELLS SOLUTION 
 
The blood was obtained from healthy voluntary donors with 0⁺ erythrocytes from the 
“Instituto de Higiene e Medicina Tropical”. The blood was collected with the help of a 
vein harvesting system using EDTA (Ethylenediamine tetraacetic acid- an anticoagulant) 
tubes, by a certified technician from the institute. The collected blood was transferred to 
falcon tubes and centrifugated at 2500 revolutions per minute (rpm) for 3 minutes (min). 
The supernatant was discarded, and sterile PBS was added to the pellet to help remove all 
the plasma and fraction of white blood cells. The centrifugation of the pellet resuspended 
in sterile PBS, was repeated 5 times to guarantee that only red-blood cells (RBCs are kept. 
After washing, the red blood cells were stored in a sterile bottle with the same amount of 
RPMIc to be at 50% haematocrit and were maintained at 4ºC. 
This protocol was optimized by our laboratory (Lobo et al., 2018). 
 
 
III.3. METHODS 
 
III.3.1. PLASMODIUM FALCIPARUM IN VITRO CULTURES 
 
• P. falciparum line 3D7 (Rosario, 1981) sensitive to chloroquine and 
mefloquine; a cryo-preserved collection of the UEI Malaria Laboratory/ IHMT;  
• P. falciparum line 3D7HT-GFP (MRA-1029, MR4, ATCC Manassas 
Virginia); provided by MR4, for distribution by BEI Resources. It is a genetic 
recombinant constructed by integration of green fluorescent protein (GFP). 
Deposited by Andrew Talman and Robert Sinden. 
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The strains were cultivated in cell culture flasks, with 5% haematocrit with 3% 
parasitaemia. The medium was changed daily to ensure a perfect development of the 
parasites. The flasks were kept in an incubator with a controlled temperature, (37ºC) and 
carbon dioxide-CO2 (5%). 
The cultures were monitored daily by smearing on slides fixed with a 100% methanol 
solution and stained with the Giemsa solution for 20 minutes. The parasites were observed 
and the parasitaemia was estimated using an optical microscope with a magnification of 
100x.  
 
III.3.2. PLASMODIUM FALCIPARUM CULTURE 
SYNCHRONISATION 
 
For some of the tests carried out, the cultures were synchronized to obtain only parasites 
with a certain age. To achieve this, the cultures were centrifugated at 2500 rpm for 3 
minutes. After that, the supernatant was discarder and the pellet resuspended in 6 mL of 
D-Sorbitol at 5% for 10 min in the incubator. Past 10 min the culture was centrifugated 
again and the supernatant discarded. The pellet was resuspended in 6mL of sterile PBS to 
wash out the D-sorbitol and centrifugate once more at 2500 rpm during 3 min.  After the 
wash with sterile PBS the culture was resuspended in RPMIc ensuring that it maintain its 
5% haematocrit.  
The parasite cultivation, monitorization and synchronization method were optimized by 
our laboratory (Machado et al., 2016; Lobo et al., 2018). 
D-sorbitol acts in the infected RBCs with mature parasites allowing to keep only RBCs 
infected with parasites in the ring stage. Mature parasites are killed by osmotic shock 
because the membrane of RBCs infected turns permeable due to structural modifications 
provoked by mature parasites (Roncalés et al., 2015). 
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III.3.3. ANTIMALARIAL ACTIVITY OF THE 
SYNTHETIZED COMPOUNDS 
 
III.3.3.1. SPEED-OF-ACTION ASSAY 
 
The half maximum inhibitory concentration (IC50) value of the compounds was 
determined using the modified protocols of the 𝐼𝐶50 speed assay described by Le Manach 
et al., 2013 and the SYBR Green I based fluorescence assay as described previously by 
Machado et al., 2016. Briefly, 3D7 culture were synchronised with 5% D-Sorbitol to have 
more than 85% of the parasites in early ring-stage 100µL of a mixture with 3% 
haematocrit containing 1% of parasitaemia, were distributed in triplicate in a 96-well 
transparent flat bottom plates. The parasites were submitted to each compound serially 
diluted (1:3) with concentrations ranging from 10,000 to 0,169 nM and incubated with 
three different incubations times (24, 48 and 72 hours). After the incubation time, the 
plates were washed with PBS and SYBR Green dye was added to the parasites for one 
hour and washed out with PBS at the end. The fluorescence intensity provoked by the 
SYBR Green dye was read by a multi-mode microplate fluorimeter reader (Triad, Dynex 
Technologies) with wavelengths excitation of 485 and emission of 535 nm.  
To calculate the percentage of survival of the parasites, the fluorescence of each well was 
calculated relatively to the negative controls (wells with untreated parasites) The 𝐼𝐶50 
value of each compound was esteemed using a nonlinear regression based on a dose-
response curve, with the help of the GraphPad Prism software (trial version). To obtain 
the Speed of Action of the compounds the ratio of 𝐼𝐶50 at 24hours/ 𝐼𝐶50 at 72hours was 
determinate; the result obtained indicated whether the compound was fast or slow acting 
(close to 1 = fast acting, close to 2 = slow acting). 
 
III.3.3.2. STAGE-SPECIFIC ACTIVITY ASSAY 
 
For the Stage Specific Activity assay the protocol used was optimized by our laboratory 
based on the Stage Specific analysis as described previously (Le Manach et al., 2013). To 
perform this essay, the 3D7-GFP culture was synchronised with 5% D-sorbitol twice (6h 
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hours apart). A mixture with 2% haematocrit and 1% parasitaemia was used for this essay. 
100µL of the mix were distributed in triplicate in a 96-well transparent flat bottom plate, 
were the parasites were challenged with 10x 𝐼𝐶50 of each compound. The plates were 
incubated with drugs (CQ, MS92, MS105, GS82) for 24 hours. After the 24h the medium 
was changed with a new medium without drugs. After 24 hours without drug, the mixture 
was diluted by 1/16 with 2% haematocrit and incubated again for 96 hours with a medium 
change after the first 48 hours. The survival and the viability of the parasites were 
evaluated by microscopy and cytometry at the beginning (T0), after the first 48 hours 
(T48) and at the end (T96) of the experiment. 
For the microscopic evaluation, a smear of the culture, at t 0h, t 48h and t 96h, was done 
and coloured with Giemsa and read on an optical microscope with a magnification of 
100x. 
The cytometer measurements performed on a CytoFLEX Blue-Red-Violet (B-R-V) Flow 
Cytometer (Beckman Coulter) equipped with 405 nm, 488 nm and 633 nm lasers. The 
following channels and probes were used: green (CM‐H2DCFDA; 492 - 495 nm 
excitation, emission 517 - 527 nm bandpass) and red (SYTOTM 61; 628 nm excitation, 
emission 645 nm bandpass). Samples were diluted to 0.5 - 1% hematocrit and 10 000 
events (encompassing uninfected and infected RBCs) were acquired based on the forward 
versus side scatter profiles. Detector gain settings varied between experiments to optimize 
signals but were kept constant within individual experiments and no compensation was 
applied to any of the channels. Analysis was performed using FlowJo Vx0.7. 
 
This experiment could have been done using the 3D7 culture, labelling it with SYBR 
Green dye. We choose to use the 3D7-GFP line because its an easy and efficient way to 
track the parasite throughout its life stages without interfering in its survival (Talman, 
Blagborough and Sinden, 2010). 
 
III.3.3.3. REACTIVE OXYGEN SPECIES QUANTIFICATION ASSAY 
 
To determine the reactive oxygen species (ROS), a mixture with 5% parasitaemia and 2% 
haematocrit was prepared using a 3D7 culture previously synchronized with 5% D-
sorbitol to begin the experience with more than 80% of the parasites in the trophozoite 
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and schizont stages. The protocol followed was optimized by our laboratory based on the 
literatures(Fu et al., 2010; Mohring, Jortzik and Becker, 2016). More precisely, 200 µL 
of the mixture was distributed in eppendorf tubes where drug treatment was carried out 
for 4 h with 10×IC50 of each compound to be tested. Chloroquine and hydrogen peroxide 
(H2O2 at 10 mM) were used as positive controls. After 4h incubation 2,5µM CM-
H2DCFDA, and 0,5µM SYTO 61, was added to the mixture and incubated for more 30 
min at 37ºC and 5% CO2. The eppendorf tubes were removed from the incubator and 
centrifugated during 1 min at 2800 rpm and washed with pbs twice. The oxidative stress 
was measured by a cytometer and the results analysed using the FlowJo software. 
 
III.3.3.4. MITOCHONDRIAL MEMBRANE POTENTIAL ASSAY 
 
The evaluation of the mitochondrial membrane potential was realised challenging an 
asynchronous mixture of 3D7 culture, with 5% parasitaemia and 2% haematocrit, for six 
hours. The mixture was distributed in eppendorf tubes and 10µM of each compound to 
be tested was added. Atovaquone was used as positive controls. After the incubation time, 
5 µM Rhodamine 123 were added to the mixture and incubated for 5 min. Past 5 min, the 
tubes were centrifugated at 2800 rpm for 1 min and washed with PBS. The pellet was 
resuspended in PBS and distributed in a 96-well black flat bottom plates and the 
fluorescence read by the multi-mode microplate fluorimeter reader (Triad, Dynex 
Technologies) (Biagini et al., 2006; Antoine et al., 2014). 
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IV.1. ANTIMALARIAL ACTIVITY OF THE SYNTHETIZED 
COMPOUNDS 
 
IV.1.1. SPEED-OF-ACTION ASSAY 
 
To better characterize the antimalarial activity of the compounds, first, a speed-of-action 
essay was performed. A half maximum inhibitory concentration (IC50) value was 
determined, at different incubation times (figure IV.1) and used to determinate the ratio 
of IC50 24h/48h and IC50 24h/72h of the controls and compounds. This essay was done 
three time in triplicates and results obtained are represented in figure IV.2-A. The IC50 
values obtained for the control drug, CQ, was  
 
 
Figure IV.1 Dose-response curves to estimate the IC50 of tested compounds and 
control drugs against Plasmodium falciparum. ATQ, Atovaquone; CQ, chloroquine; 
MS105, GS92, MS92 newly synthetized compounds.  
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similar at the different incubation times, with ratio of 1,0 for both IC5024h/IC5048h and 
IC5024h/ IC5072h. These ratios are in accordance with literature (Le Manach et al., 2013). 
These results were expected, since CQ is known to be a fast-acting drug, that is, it has a 
fast parasite clearance time (C. D. Fitch; D. C. Warhurst, 1986). For the other control 
drug, ATQ, the IC50 values obtained were similar after 24 hours and 48 hours incubations 
and different after 72h (p=0,0010; Mann-Whitney) (figure IV.2-B). Hence, for ATQ, the 
correspondent ratios were 1,0 for IC5024h/ IC5048h and 2.6 for IC5024h/ IC5072h (figure 
IV.2-A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV.2. Speed-of-action of the diferent compounds using Plasmodium 
falciparum 3D7 strain. A) IC50 values determined at diferent incubation times (24h, 48h and 
72h) and the IC50 ratios. B) graphical representation of the IC50 values of the compounds (MS92, 
MS105, GS82) and the control drugs; chloroquine (CQ)and atovaquone (ATQ), at 24h, 48h and 
72h incubations. ** p=0,0010; Mann Whitney test. 
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ATQ is known to be a slow-acting drug as it need more time in contact with the parasite 
to eliminate it from the bloodstream (Nixon et al., 2013), this behaviour was reflected by 
the ratio 24h/72h obtained (figure IV.2-A) and is in agreement with other authors (Sanz 
et al., 2012; Le Manach et al., 2013; Wilson et al., 2013). However, the 24h/48h ratio was 
± 1 (figure IV.2-A), a value expected from a fast, rather than a slow-acting drugs (Wein 
et al., 2010; Sanz et al., 2012; Le Manach et al., 2013). This might mean that isolated, the 
ratio 24h/48h is not potent enough to discriminate slow from fast acting drugs. 
Regarding the tested compounds, MS105 presented an IC5024h/IC5072h ratio of 1,0 
whereas MS92 and GS82 presented an IC5024h/IC5072h ratio below 1(figure IV.2-A). 
The IC5024h/IC5072h ratio value obtained for the MS105 compound indicate that it can 
be considered as a fast-acting compound (Sanz et al., 2012; Le Manach et al., 2013) since 
it is similar to the IC5024h/IC5072h ratio obtained for CQ. 
The IC5024h/IC5072h ratio values obtained for the MS92 and GS82 compounds remained 
below 1, indicating that this result alone may be inconclusive to determinate the speed-
of-action of these two compounds. 
The elevated standard deviation (figure IV.2-A), obtained in the IC50 values of the 
compounds (GS82, MS92,MS105) can be explained by the fact that these compounds are 
new synthetized compounds and they might not be as stable as the controls.  
 
 
IV.2. STAGE-SPECIFIC ASSAY 
 
The second experiment to characterize the antimalarial activity of the synthetised 
compounds was to determinate the stage-specif activity. The aim of this essay was to 
determinate if the compounds where more active against a particular stage of development 
of the parasite. As described earlier, the 3D7-GFP culture used for this experiment was 
synchronized with sorbitol, in order to obtain cultures enriched with rings or trophozoits 
at the beginning of the experiment. 
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A) OPTICAL MICROSCOPY VS FLOW CYTOMETRY 
 
Synchronization was verified and parasitemia determined in paralel by optical 
microscopy and flow cytometry analysis after incubation times (t0h and t48h).  
Histogram of (green GFP fluorescence) synchronized cultures of Plasmodium falciparum 
strain 3D7-GFP, after 48 hours incubation (t48h), under standard culture conditions and 
the respcetive picture of the diferent stages are presented in figure IV.3. The histogram, 
Figure IV.3. Flow cytometry histograms for ring- and trophozoite-stage 
synchronized cultures of P. falciparum strain 3D7-GFP strain. Dotted black line, ring-
stage parasites; Solid black line, trophozoites-stage parasites. Insert pictures of ring- and 
trophozoite-stage parasites after 48 hours incubation (t48h), under standard culture conditions. 
 
 
made using the results obtained using the cytometer and analised with the Flowjo Vx 0,7 
software, show the fluorescence intensity emitted by the diferent stages of the parasite. It 
can be observed that the parasites in the ring-stage, had lower fluorescence, close to the 
unparasited red blood cells (RBCs). The parasites in the trophozoite-stage, showed a 
higher green fluorescence. The fluorescence intensity of the trophozoite-stage parasites 
were about 10 fold higher than those of the ring-stage parasites as described in the 
literature (Schuck et al., 2011). 
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Parasitaemia obtained by optical microscopy and flow cytometry analysis after the same 
incubation time (t0h and t48h) were compared in order to validate the cytometer analises 
and poursuite the examination of the results focussing only on the cytometer results. 
These parasitaemias obtained by optical microscopy and flow cytometry are presented in 
table IV.1  
 
 
Table IV.1. Parasitaemia obtained by optical microscopy and flow cytometry. 
 
Cyt. – flow cytometry; OM. – optical microscopy. 
 
 
From the values presented in table IV.1, we concluded that, the % of parasitaemia 
determined by optical microscopy or by flow cytometry were identical, hence alowing us 
to use flow cytometry to study the stage specific effect of the new compounds. 
 
B) STAGE-SPECIFIC ACTIVITY DETERMINATION 
 
Histogram of (green GFP fluorescence) synchronized cultures of Plasmodium falciparum 
strain 3D7-GFP, after 48 hours incubation (t48h), under standard culture conditions, 
presented in figure IV.4, shows the fluorescence intensity emitted by the different stages 
of the parasite after challenge with the compounds (MS92; MS105; GS82) and the control 
drug chloroquine. It can be observed that, parasites challenged with CQ had the lowest 
fluorescence intensity in both stages. The ring-stages parasites challenged with the 
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compounds had higher fluorescence intensity but lower than the untreated parasites 
(figure IV.4-A). The trophozoite-stage parasites challenged with the compounds MS92 
and MS105 show similar fluorescence intensity between them, but lower than the 
fluorescence intensity of the untreated parasites. The parasites challenged with the 
compound GS82 show a fluorescence intensity similar to those of the untreated parasites 
(figure IV.4-B). 
The efficacy of the compounds was analysed using the Mann-Whitney test and presented 
in figure IV.5. 
 
Figure IV.4. Flow cytometry histograms of stage dependent effects of the compounds 
and chloroquine. Histograms of (green GFP fluorescence) synchronized cultures of 
Plasmodium falciparum after 48h (t 48h) incubation time. A) ring-stage parasites. B) trophozoite-
stages parasites. Filled black, CQ; filled grey, MS105; dotted black line, MS92; heavy dashed 
black line, GS82, solid black line; CTL.  
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Chloroquine showed to have similar activity against ring- and trophozoite-stage parasites 
after 48 hours incubation (t 48h), presenting an efficacy of 88% in both stages of the 
parasite (figure IV.5). This behaviour was expected since CQ is known to influence the 
growth of all parasites stages similarly (Maerki et al., 2006; Le Manach et al., 2013). 
The compound MS92 showed a stage-specific profile of activity similar to CQ, with a 
similar activity against both stages of the parasite (figure IV.5). 
The compounds MS105 and GS82, however, presented higher activity against ring-stage 
parasites (p= 0,0173; p= 0,0022; Mann-Whitney respectively) (figure IV.5). 
 
There was no significant difference between the two potential PfPDE inhibitors activity 
against the parasites. MS92 and MS105 were more active against both parasite stages (p= 
0,0043; Mann-Whitney) than the potential PfDHODH inhibitor compound GS82 (figure 
IV.5). 
 
From the literature, it’s known that the P. falciparum genome encodes two PDEs (PfPDEα 
and PfPDEβ) that are expressed in asexual blood stage reproduction (Baker et al., 2017b), 
but there is no knowledge in which stage of the parasite they’re expressed yet. Given the 
fact that these two compounds (MS92 and MS105), that were synthesized to be 
phosphodiesterase (PDEs) inhibitors, acts against both stages of the parasite, corroborates 
with the literature. The fact that the compound MS105 is more active against the ring-
stage parasite, give new insights into the mode of action of the compound. 
 
It is known from the literature that the PfDHODH is essential for the cell growth of the 
parasite (Phillips and Rathod, 2010), but there is no knowledge if they have a particular 
action in the stages development of the parasite. The fact that the compound GS82 (a 
potential PfDHODH inhibitor), showed a predominant activity against the ring-stage 
parasites (p= 0,0022; Mann-Whitney) (figure IV.5), suggest that the mode of action of 
this compound is suitable for further experiments to confirm its activity. Being active 
against the ring-stage parasites could be a suitable characteristic since there is evidence 
that resistances against antimalarial drugs may occurs in the ring-stages parasites (Blasco, 
Leroy and Fidock, 2017). 
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Figure IV.5. Stage dependent effect of the new compounds and chloroquine, on 
synchronous culture of Plasmodium falciparum strain 3D7-GFP at t48h. Compound 
efficacy are expressed as the percentage of death relative to an untreated control. CQ, chloroquine; 
GS82-MS92-MS105, new compounds. R, ring-stage parasites (empty bars); T, trophozoite-stage 
parasites (filled bars). ** P=0,0022; * P=0,0173. Mann-Whitney test. 
 
 
 
C) CYTOCIDAL VS CYTOSTATIC EFFECT OF COMPOUNDS 
 
Cultures of Plasmodium falciparum strain 3D7-GFP were challenged with CQ and the 
compounds (MS92, MS105, GS82) for 24 hours. After 24h, the medium was changed 
with new medium without drug and incubated for more 24h. After which the cultures 
were incubated for additional 96 hours as indicated in section III.3.3.2. Extending the 
stage-specific assay until 96 hours (t96h) allowed us to estimate if compounds had 
cytocidal or cytostatic effect on the parasite growth, by analysing whether the parasites 
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were able to recover from the damage caused by the compounds (Michelle F Paguio, 
Bogle and Roepe, 2011). 
 
Histogram of (green GFP fluorescence) synchronized cultures of Plasmodium falciparum 
strain 3D7-GFP, after 96 hours incubation (t96h), under standard culture conditions, 
presented in figure IV.5. The histogram shows the fluorescence intensity emitted by the 
different stages of the parasite after changing the medium, allowing them to grow with no 
constraint. It can be observed that, the parasites previously challenged with CQ, had the 
lower fluorescence intensity in both stages of the parasite. The ring-stages parasites that 
were previously challenged with the compounds (MS92; MS105; GS82) had higher 
fluorescence intensity than the parasites challenged with CQ, but lower than the untreated 
parasites (figure IV.6-A). The trophozoite-stages parasites challenged with the 
compounds MS92 and MS105 show similar fluorescence intensity between them, but 
lower than the untreated parasites. The parasites challenged with the compound GS82, on 
the other hand, show a fluorescence intensity similar to the untreated parasites (figure 
IV.6-B). 
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Figure IV.6. Flow cytometry histograms of stage dependent effect of the compounds 
and chloroquine. Histograms of (green GFP fluorescence) synchronized cultures of 
Plasmodium falciparum after 96h. t 96h, incubation time; filled black, CQ; filled grey, MS105; 
dotted black line, MS92; heavy dashed black line, GS82; solid black line; CTL (untreated culture).  
 
The efficacy of the compounds was analysed using the Unpaired t test and presented in 
figure IV.7. 
 
After 96 hours incubation without drug, we could observe that chloroquine had an 
efficacy > 95% in the ring- and trophozoite-stage of the parasites. This behaviour was 
expected since CQ is known to be a cytocidal drug and that can to induce growth 
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inhibition and irreversible morphological changes in both stages of the parasite (Maerki 
et al., 2006; Le Manach et al., 2013; Roepe, 2014). 
The compound MS105 presented an efficacy against the ring-stage parasites (± 94%), 
similar to CQ (figure IV.7). Its efficacy against the trophozoite-stage parasite was a little 
bit inferior (83 %) (p=0,0238, Mann-Whitney). Considering the low percentage( < 20%) 
of parasites of both stages that manage to recover from drug treatment (Michelle F Paguio, 
Bogle and Roepe, 2011) at t96h, we can conclude that MS105 had a more cytocidal effect. 
 
Regarding the effect of the compound MS92, we could observe that it was a little more 
efficient against the ring-stage parasite (± 89%) than against the trophozoite-stage 
parasites (±77%), (p=0,0238, Mann-Whitney) (figure IV.7). It can be considered a 
cytocidal compound since most parasites (> 75%) (Michelle F. Paguio, Bogle and Roepe, 
2011) couldn’t recover after the drug treatment. 
 
Compounds MS92 and MS105 presented no difference between their toxicity against the 
trophozoite-stage of the parasite, however, MS105 was more toxic to ring-stage parasites 
(p=0,00021, Unpaired t test) than MS92 (figure IV.7).  
 
Figure IV.7. Stage dependent effect of the new compounds and chloroquine on 
synchronous culture of Plasmodium falciparum strain 3D7-GFP after 96 hours. 
Compound efficacy are expressed as the percentage of death relative to an untreated control. The 
empty bars represent the ring-stage parasites (R) and the filled bars represent the trophozoite-
stage parasites (T). *** p=0,0004; ** p=0,00021; **** p<0,0001. Unpaired t test. 
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Compound GS82, presented higher toxic activity against ring- (> 75%) parasites 
(p=0.0004, Unpaired t test) than against trophozoite-stage (< 10%) parasites (figure IV7) 
at t96h. This compound seems to have a variable toxicity depending on the stage of the 
parasite: cytocidal against the ring-stage parasites and cytostatic against the trophozoite-
stage parasites. When a compound has different effect on different stages of the parasite, 
it can be due to the dose of the compound used, or due to the age of the parasite used at 
the begin of the experiment (Roepe, 2014). 
 
Analysing all the compounds regarding their toxicity, it appears that the potential PfPDE 
inhibitors (MS92 and MS105) exerted a cytocidal effect against both stages of the 
parasite, on the other hand the PfDHODH inhibitor appear to be cytocidal against the 
ring-stage parasites and presenting a more cytostatic effect against the trophozoite-stages 
parasites. Most of the trophozoite-stage parasites were able to recover after the contact 
with GS82 (figure 7).  
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IV.3. REACTIVE OXYGEN SPECIES QUANTIFICATION ASSAY 
 
For the determination of the reactive oxygen species (ROS) assay, CM‐H2DCFDA was 
combined with SYTO 61 (nucleic acid dye) to monitor oxidative stress variation at 
different parasite-stages as it is performed and validated in the literature (Mohring, Jortzik 
and Becker, 2016; Mohring et al., 2017; Gunjan et al., 2018). When the reduced form of 
CM-H2DCFDA is added to cells, it diffuses freely across membranes. Oxidation of 
H2DCF by reactive oxygen species (especially hydrogen peroxide in the presence of iron 
or hematin) produces highly fluorescent 2’,7’dichlorofluorescein (here on designated as 
DCF)(Fu et al., 2010). 
 
Asynchronous cultures (P. falciparum 3D7) where treated as described in section 
III.3.3.3. Results were analysed by flow cytometry and reinforced by microscopic 
analysis. No compensation was need when using the flow cytometry since the dyes used 
for this experiment were different and there was no overlap in the detector of the colours 
used (Roederer, 2001). 
 
Analysing the results obtained using untreated parasites, we could identify the DCF 
fluorescence of the parasites based on the 2‐dimensional plots of DCF (green) and SYTO 
61 (red) fluorescence. Gates were set in mode to differentiate the uninfected RBCs 
population, the ring-stage and the trophozoite-stage population. 
 
Initially we labelled the parasites with only DCF, then only with SYTO 61 and finally 
with DCF and SYTO 61 as demonstrated in figure IV.8. The parasites labelled with only 
DCF (figure IV.8-a), exhibit a low green signal but show a small population (Q1) 
exhibiting increased DCF fluorescence. When labelled with SYTO 61 alone. a population 
with different levels of red signal are distinguished but all exhibit a low green signal (Q3) 
(Figure IV.8 b). When labelled with DCF and SYTO 61, a small unsynchronised 
population exhibiting different levels of red and green signal can be observed (Q2 and 
Q3) (figure IV.8-c). It is related in the literature, (Fu et al., 2010; Mohring, Jortzik and 
Becker, 2016), that the ring-stage (Q3) parasites exhibit a DCF signal that is similar to 
that of the uninfected RBCs (Q4), whereas the trophozoite-stage (Q2) parasites are 
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associated with a greater DCF signal and in uninfected cultures both the red and green 
signals are low (Q4) (figure IV.8 a, b and c). Even though the parasites observed are 
unsynchronized, the gates help us to differentiate the different stages of the parasites and 
confirm that the results obtained are in line with what was observed in the literature.  
Considering that the trophozoite-stage parasites are associated a greater DCF signal, it 
would be suitable for monitorization of oxidative stress variation caused by drugs to be 
done using preferentially trophozoite-stages parasite so the results can be more consistent 
and precise. 
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Figure IV.8. DCF signals in the ring and trophozoite stages parasites. Red blood cells 
labelled with CM-H2DCFDA and SYTO 61(a) and asynchronous 3D7 cultures labelled with CM-
H2DCFDA (b), SYTO 61 (c), CM-H2DCFDA and SYTO 61 (d), (as indicated in each panel), 
analysed by flow cytometry and imaged using a fluorescence microscope. Two-dimension plots 
of the red and green fluorescence intensity are presented. 
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IV.4. MITOCHONDRIAL MEMBRANE POTENTIAL ASSAY 
 
For the evaluation of the mitochondrial membrane potential assay, atovaquone (ATQ) 
was used as control drug because of it known activity against the mitochondria by 
inhibiting the mitochondrial electron transport and depolarization of mitochondrial 
membrane, causing death of the parasite (Srivastava, Rottenberg and Vaidya, 1997; 
Biagini et al., 2006; Nixon et al., 2013). Rhodamine 123 (a cationic fluorescent dye) was 
used to monitor the membrane potential of the mitochondria. The dye distributes 
according to the negative membrane potential across the mitochondrial inner membrane. 
The loss of membrane potential results in the loss of the dye and, therefore, the 
fluorescence intensity (Chazotte, 2011; Antoine et al., 2014). 
Atovaquone, the selective bc1 complex inhibitor, showed a decrease of the total 
membrane potential dependent ﬂuorescence by proximally 16% (figure IV.8). This 
behaviour was expect since its known in the literature that ATQ can reduce the total 
membrane potential dependent fluorescence up to 30% (Biagini et al., 2006; Antoine et 
al., 2014).  
 
The compound MS92 showed a decrease of fluorescence of ± 13%, while the compound 
MS105 and GS82 showed a decrease of ± 7% and ± 9% respectively (figure IV.9). The 
compound MS92 showed to have an activity more similar to ATQ despite the significative 
statistical difference observed (p=0,0411, Mann-Whitney). 
 
Results obtained by the compound MS92 (a potential PfPDE inhibitor) could be expected, 
since several studies suggested that PDEs have an intramitochondrial activity (Acin-Perez 
et al., 2009, 2011; Monterisi et al., 2017). Since this compound is the only one to show 
results more similar to ATQ, suggest that MS92 could have an important role in the 
parasite mitochondria. The fact that MS105 (a potential PfPDE inhibitor too) showed 
small decrease effect in the membrane potential, suggest that only a specific PfPDE 
inhibitor can impact the mitochondria PfPDE’s activity. 
 
According to the literature, DHODH can be found in the mitochondrial intermembrane 
space (Fang et al., 2013), it was expected that the compound GS82 (a potential PfDHODH 
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inhibitor) provoked a higher decrease of the membrane potential dependent fluorescence. 
That was not observed, GS82 induced a small membrane potential dependent 
fluorescence decrease (Fig. IV.9). 
 
These methodologies showed to be adequate to estimate the mitochondrial membrane 
potential interference of new compounds, but more experiments are needed to confirm 
the compounds behaviour. 
 
 
Figure IV.9.  Effect of Atovaquone (ATQ) and the synthetized compounds (GS82- 
MS92- MS105) on mitochondrial membrane potential of Plasmodium falciparum 
strain 3D7. Each bar represents the mean from experiments performed independently ± standard 
errors, done in triplicate (n=6). **P=0,0022; *1 P=0,0411; *2 P=0,0152. Mann-Whitney test. 
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Regarding the speed-of-action assay, we could conclude that of the three compounds 
tested, the compound MS105 was the only one to present a fast-acting profile. The results 
obtained for the compounds MS92 and GS82 suggest that they are slow-acting 
compounds. 
When analysing the stage-specific essay, we could conclude that of the three compounds, 
the compound MS105 had a higher activity against the ring-stages parasites, and GS82 
had a similar activity against both stages of the parasite. MS92 and MS105 have a 
cytocidal activity profile while GS82 seem to have a cytocidal effect against the ring-
stage parasite, and a cytostatic effect against the trophozoite-stage parasites. 
Combining the speed-of-action and the stage-specific assays, described here, we have a 
valid and fast approach to discriminate between fast- and- slow-acting, cytocidal and 
cytostatic antimalarials compounds, providing valuable information to guide and 
accelerate the development of new classes of antimalarial compounds. 
The optimized ROS protocol demonstrate that, using CM-H2DCFDA to assess oxidative 
stress in the parasites, combined with SYTO 61, is reliable. The results obtained here are 
in line with previous observations and suggests that the combination of these two 
fluorescence-based probes, could facilitate the monitorization of the effects of different 
metabolic inhibitors and provide more insight mechanisms of anti-malarial drug action. 
The optimized mitochondrial membrane potential assay showed that the results for 
atovaquone were in line with previous observations. Suggesting that the use of 
Rhodamine 123 to monitor the membrane potential is consistent and can provide more 
insights into the mechanism of anti-malarial drug action. 
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Table I: Ring-stage parasitaemia counted by microscope as opposed to parasitaemia got 
by cytometer and the respective percentage of efficacy of each compound at T48h and 
T96h. 
 
*K: Untreated culture 
 
 
 
 
 
 
 
Rings 
 Optical microscopy Flow cytometry 
48h %Parasitaemia 
% Efficacy of 
compounds 
%Parasitaemia 
% Efficacy of 
compounds 
K* 2,67 0,0 2,35 0,0 
CQ 0,33 87,5 0,34 85,5 
105 1,07 59,7 0,93 60,3 
82 1,55 41,8 1,33 43,3 
92 1,03 61,4 1,02 56,6 
96h     
K* 6,80 0,0 3,99 0,0 
CQ 0,06 99,2 0,04 99,0 
105 0,26 96,1 0,21 94,7 
82 1,90 72,1 1,41 64,7 
92 0,57 91,7 0,35 91,3 
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Table II: Trophozoites-stage parasitaemia counted by microscope as opposed to 
parasitaemia got by cytometer and the respective percentage of efficacy of each 
compound at T48h and T96h. 
 
*K: Untreated culture 
 
 
 
 
Trophozoites  
 Optical microscopy Flow Cytometry 
48h %Parasitaemia 
% Efficacy of 
compounds 
%Parasitaemia 
% Efficacy of 
compounds 
K* 1,42 0,0 1,65 0,0 
CQ 0,10 93,1 0,18 89,1 
105 0,52 63,6 0,66 60,3 
82 1,02 27,8 1,15 30,6 
92 0,61 56,9 0,66 60,1 
96h     
K* 1,57 0,0 1,37 0,0 
CQ 0,05 96,8 0,03 98,1 
105 0,21 86,4 0,23 83,4 
82 1,43 9,0 1,25 8,2 
92 0,38 76,1 0,32 76,8 
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Figure I: Stage-Specific assay: flow cytometry analysis of ring-stage parasites. 
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Figure II: Stage Specific assay: flow cytometry analysis of trophozoite-stages parasites. 
 
